Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine 

Stock Information for Channel Therapeutics Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Channel Therapeutics Corporation

Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
Chromocell to Present at Upcoming Fall Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.